Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI.

Curr Biol. 2005 Feb 8;15(3):249-54.

2.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG.

Oncogene. 2009 Jun 11;28(23):2289-98. doi: 10.1038/onc.2009.95. Epub 2009 Apr 27.

3.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
4.

The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X.

Am J Pathol. 2009 Jun;174(6):2367-77. doi: 10.2353/ajpath.2009.081057. Epub 2009 Apr 23.

5.

NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

Tschandl P, Berghoff AS, Preusser M, Burgstaller-Muehlbacher S, Pehamberger H, Okamoto I, Kittler H.

PLoS One. 2013 Jul 8;8(7):e69639. doi: 10.1371/journal.pone.0069639. Print 2013.

6.

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.

Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N, Marais R.

Nature. 2014 Jul 24;511(7510):478-82. doi: 10.1038/nature13298. Epub 2014 Jun 11.

7.

Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.

Wu J, Rosenbaum E, Begum S, Westra WH.

Am J Dermatopathol. 2007 Dec;29(6):534-7.

PMID:
18032947
8.

C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S, Wawrzyniak JA, Berman AE, Giordano TJ, Prochownik EV, Soengas MS, Nikiforov MA.

Oncogene. 2008 Nov 6;27(52):6623-34. doi: 10.1038/onc.2008.258. Epub 2008 Aug 4.

9.

Benign nodal nevi frequently harbor the activating V600E BRAF mutation.

Taube JM, Begum S, Shi C, Eshleman JR, Westra WH.

Am J Surg Pathol. 2009 Apr;33(4):568-71. doi: 10.1097/PAS.0b013e31818a64fb.

PMID:
19033861
10.

High frequency of BRAF mutations in nevi.

Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS.

Nat Genet. 2003 Jan;33(1):19-20. Epub 2002 Nov 25.

PMID:
12447372
11.

Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.

Shelly S, Chien MB, Yip B, Kent MS, Theon AP, McCallan JL, London CA.

Mamm Genome. 2005 Mar;16(3):211-7.

PMID:
15834638
12.

Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.

Cohen Y, Rosenbaum E, Begum S, Goldenberg D, Esche C, Lavie O, Sidransky D, Westra WH.

Clin Cancer Res. 2004 May 15;10(10):3444-7.

13.

BRAF kinase in melanoma development and progression.

DeLuca AM, Srinivas A, Alani RM.

Expert Rev Mol Med. 2008 Feb 18;10:e6. doi: 10.1017/S1462399408000604. Review.

PMID:
18279546
14.

Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.

Turner DJ, Zirvi MA, Barany F, Elenitsas R, Seykora J.

J Cutan Pathol. 2005 May;32(5):334-9.

PMID:
15811117
15.

Inducible BRAF suppression models for melanoma tumorigenesis.

Hoeflich KP, Jaiswal B, Davis DP, Seshagiri S.

Methods Enzymol. 2008;439:25-38. doi: 10.1016/S0076-6879(07)00403-X.

PMID:
18374154
16.

Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.

Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA.

Am J Surg Pathol. 2013 Mar;37(3):413-20. doi: 10.1097/PAS.0b013e318271249e.

PMID:
23211290
17.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS.

Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1.

18.

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.

Wong CW, Fan YS, Chan TL, Chan AS, Ho LC, Ma TK, Yuen ST, Leung SY; Cancer Genome Project.

J Clin Pathol. 2005 Jun;58(6):640-4. Review.

19.

Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.

Yeh AH, Bohula EA, Macaulay VM.

Oncogene. 2006 Oct 26;25(50):6574-81. Epub 2006 May 22.

PMID:
16715137
20.

Oncogenic Braf induces melanocyte senescence and melanoma in mice.

Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R.

Cancer Cell. 2009 Apr 7;15(4):294-303. doi: 10.1016/j.ccr.2009.02.022.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk